Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers

Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Jie Yi, Liwen Ren, Dandan Li, Jie Wu, Wan Li, Guanhua Du, Jinhua WangAbstractBreast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue. The aim of this study was to investigate the function of TFF1 in BCs, and to assess whether serum TFF1 could be used in formulating a prognosis for BC patients. In silico analyses were carried out to determine the expression of TFF1 mRNA in different types of BC and the association between TFF1 expression and survival of BC patients. Expression of TFF1 protein was checked in 52 paraffin-embedded tissues of BCs by immunochemistry, and serum concentration of TFF1 in 70 BC patients and 32 healthy controls was measured by ELISA. Functional activities of TFF1 in BC cells were determined by CCK-8 assay, colony formation, BrdU-DNA synthesis, and assays for migration and invasion. Results showed that expression of TFF1 mRNA was correlated with expression of biomarkers of luminal cancers including ESR1, GATA3, FOXA1, MYB and XBP1. In addition, patients with ER+BC had higher expression of TFF1 than those with ER- (p
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research

Related Links:

Oncology News Burst
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractThe median age for breast cancer diagnosis is 62  years, but a disproportionate number of patients are over the age of 75 years and the majority of those have hormone receptor-positive, human epidermal growth factor receptor-2 (HER2)-negative cancers. This review provides a logical algorithm to guide providers through the many complicated issue s involved in adjuvant systemic therapy decisions in older patients with hormone receptor-positive, HER2-negative breast cancer. For this subtype of breast cancer, the mainstay of treatment is surgery and adjuvant endocrine therapy with tamoxifen or an aromata...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
Conclusion: Eribulin is an effective new treatment option in heavily pretreated MBC, with a manageable toxicity profile. Our results confirm that treatment with eribulin is feasible and safe in real-world patients.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
ConclusionsThe efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
A patient with HER2-positive early breast cancer (BC) developed dermatomyositis (DM), which disappeared after the first administration of adjuvant trastuzumab. No HER2 overexpression/amplification was observed in DM skin biopsies. Both BC and skin immune infiltrates were composed mostly of CD3+ T-lymphocytes. Interestingly, tumor-infiltrating lymphocytes expressed PD-1, which was negligible in skin-infiltrating lymphocytes, while both BC cells and keratinocytes were PD-L1-positive. High serum levels of endogenous anti-HER2 antibodies were detected, confirming the induction of a HER2-specific adaptive immune response. It ma...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Molecules, Vol. 25, Pages 1025: Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer Molecules doi: 10.3390/molecules25051025 Authors: Edyta Cędrowska Marek Pruszyński Weronika Gawęda Michał Żuk Paweł Krysiński Frank Bruchertseifer Alfred Morgenstern Maria-Argyro Karageorgou Penelope Bouziotis Aleksander Bilewicz It has been proven and confirmed in numerous repeated tests, that the use of a combination of several therapeutic methods gives muc...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Conditions:   Advanced Solid Tumor;   Breast Neoplasms Interventions:   Drug: BPI-1178;   Drug: Fulvestrant;   Drug: Letrozole Sponsor:   Beta Pharma (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Statistics | Study | Women